IOVS British Journal of Pharmacology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1167/iovs.08-2473 on August 15, 2008
 (Investigative Ophthalmology and Visual Science. 2009;50:1-4.)
© 2009 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.08-2473
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
iovs.08-2473v1
50/1/1    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davis, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davis, M. D.

Effect of Ruboxistaurin on the Visual Acuity Decline Associated with Long-standing Diabetic Macular Edema

Matthew D. Davis,1 Matthew J. Sheetz,2 Lloyd P. Aiello,3 Roy C. Milton,4 Ronald P. Danis,1 Xin Zhi,2 Aniz Girach,5 Maria C. Jimenez,2 Louis Vignati2 for the PKC-DRS2 Study Group

1From the Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, Wisconsin; 2Lilly Research Laboratories, Indianapolis, Indiana; the 3Beetham Eye Institute, Joslin Diabetes Center and Department of Ophthalmology, Harvard University Medical School, Boston, Massachusetts; 4EMMES Corporation, Rockville, Maryland; and 5Lilly Research Laboratories, Windlesham, Surrey, United Kingdom.

PURPOSE. To compare relationships between severity and duration of diabetic macular edema (DME) and visual acuity (VA) observed in the PKC-DRS2 with those from the Early Treatment Diabetic Retinopathy Study (ETDRS) and to assess the effect of the orally administered PKC β inhibitor ruboxistaurin (RBX) on these parameters.

METHODS. In the PKC-DRS2, patients with moderately severe to very severe nonproliferative diabetic retinopathy (n = 685) were randomly assigned to 32 mg/d RBX or placebo and followed up for 36 months with ETDRS VA measurements and fundus photographs (FP) every 3 to 6 months. Mean VA was calculated across all FP visits for eyes in each level of the ETDRS DME severity scale at those visits. For eyes with baseline VA ≥ 20/40, relationships between change in VA from baseline to last visit and duration of severe DME were analyzed with linear regression.

RESULTS. Mean VA decreased by approximately 22 letters between the mildest and most severe levels of the DME scale in the PKC-DRS2, compared with 27 letters in the ETDRS. In the placebo group, the rate of decrease in VA over time associated with duration of severe DME was 0.67 letters per month (24 letters over 36 months, compared with 20 letters over 28–36 months in the ETDRS). This rate was 30% less in the RBX group (0.47 letter per month, P = 0.022).

CONCLUSIONS. The VA decrease in the PKC-DRS2 associated with long-standing DME agrees well with estimates from the ETDRS. RBX appears to ameliorate this decrease, an effect that could be important clinically. (ClinicalTrials.gov number, NCT00604383.)






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by the Association for Research in Vision and Ophthalmology